Ledezma-Acevedo JA, González-Méndez JG, Calderón-Rivera D

Language: Spanish
References: 23
Page: 48-56
PDF size: 333.43 Kb.

ABSTRACT

Bipolar Disorder is a psychiatric condition highly disabling, with elevated rates of psychiatric and medical comorbidities that contribute substantially to morbidity and mortality. Pathophysiology of the illness is not well known but recent biologic and pharmacological studies suggest that altered receptormediated signal transduction mechanisms contribute to the pathophysiology of the disease. Accordingly, medications with effect in these signal transduction mechanisms are supposed to be useful in the treatment of Bipolar Disorder, such is the case of tamoxifen. Animal model studies and clinical trials have been conducted to address the efficacy and side-effect profile of tamoxifen. AIMS: To review the clinical studies that have evaluated the effects of tamoxifen in manic phase of BD. Method: It was conducted a systematic literature search on PubMed and other science databases looking for clinical studies that used tamoxifen for the treatment of Bipolar Disorder in mania phase. Results: A limited number of clinical studies concerning the effect of tamoxifen as a treatment in bipolar patients were identify, also it was found some studies of tamoxifen in animal models of mania. Conclusion: Mechanism of action of tamoxifen suggests that it could be useful in patients with manic episodes; however, more evidence is desirable to evaluate the efficacy of tamoxifen in different clinical profiles of patients with bipolar disorder.

REFERENCES

1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders (DSM-5®). American Psychiatric Pub, 2013.

2. Maximov PY, McDaniel RE, Jordan VC. Th e Legacy of Tamoxifen. In: Tamoxifen. Milestones in Drug Th erapy. Springer, Basel; 2013.

3. Mallingera AG, Th ase ME, Haskett R, Buttenfi eld J, Luckenbaugh DA, Frank E, et la. Verapamil augmentation of lithium treatment improves outcome in mania unresponsive to lithium alone: preliminary fi ndings and a discussion of therapeutic mechanisms. Bipolar Disorders. 2008; 10(8): 856–866

4. Malhi GS, Tanious M, Das P, Coulston CM, Berk M. Potential mechanisms of action of lithium in bipolar disorder. Current understanding. CNS Drugs. 2013; 27(2):135-53.

5. Whiteford HA, Degenhardt L, Rehm J, Baxter AJ, Ferrari AJ, Erskine HE, et al. Global burden of disease attributable to mental and substance use disorders: fi ndings from the Global Burden of Disease Study 2010. Th e Lancet. 2013; 382(9904):1575-1586.

6. McIntyre RS, Konarski JZ, Yatham LN. Comorbidity in bipolar disorder: a framework for rational treatment selection. Human Psychopharmacology: Clinical and Experimental. 2004; 19(6):369-86.

7. Manji HK, Quiroz JA, Payne JL, Singh J, Lopes BP, Viegas JS, et al. Th e underlying neurobiology of bipolar disorder. World Psychiatry. 2003; 2(3):136-146.

8. Kulkarni J, Garland KA, Scaffi di A, Headey B, Anderson R, De Castella A, et. al. A pilot study of hormone modulation as a new treatment for mania in women with bipolar aff ective disorder. Psychoneuroendocrinology. 2006; 31(4): 543–547.

9. Zarate CA Jr, Singh JB, Carlson PJ, Quiroz J, Jolkovsky L, Luckenbaugh DA et al. Effi cacy of a protein kinase C inhibitor (tamoxifen) in the treatment of acute mania: a pilot study. Bipolar Disorders 2007: 9(6): 561–570.

10. Yildiz A, Guleryuz S, Ankerst DP, Ongür D, Renshaw PF. Protein Kinase C Inhibition in the Treatment of Mania. A Double-blind, Placebo-Controlled Trial of Tamoxifen. Archives of general psychiatry 2008; 65(3):255-263.

11. Amrollahi Z, Rezaei F, Salehi B, Modabbernia AH, Maroufi A, Esfandiari GR, et al. Double-blind, randomized, placebocontrolled 6-week study on the effi cacy and safety of the tamoxifen adjunctive to lithium in acute bipolar mania. Journal of Aff ective Disorders 2011; 129(1): 327–331.

12. Kulkarni J, Berk M,Wang W,Mu L,Scarr E,Van Rheenen. TE. Et al A four week randomised control trial of adjunctive medroxyprogesterone and tamoxifen in women with mania. Psychoneuroendocrinology 2014; 43: 52-56.

13. Einat, H, Manji, HK. Cellular plasticity cascades: genes-tobehavior pathways in animal models of bipolar disorder. Biological. Psychiatry 2006; 59(12): 1160–1171

14. Sabioni P, Baretta IP, Ninomiya EM, Gustafson L, Rodrigues AL, Andreatini R. Th e antimanic-like eff ect of tamoxifen: Behavioral comparison with other PKC-inhibiting and antiestrogenic drugs. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2008; 32 (8):1927–1931.

15. Moretti M, Valvassori SS, Steckert AV, Rochi N, Benedet J, Scaini G. et al Tamoxifen eff ects on respiratory chain complexes and creatine kinase activities in an animal model of mania. Pharmacology, Biochemistry and Behavior. 2011; 98(2):304–310.

16. Steckert AV, Valvassori SS, Mina F, Lopes-Borges J, Varela RB, Kapczinski F, et al. Protein Kinase C and Oxidative Stress in an Animal Model of Mania Amanda Current neurovascular research; 2012 9(1): 47-57.

17. Cechinel-Recco K, Valvassori SS, Varela RB, Resende WR, Arent CO, Vitto MF.et al Lithium and tamoxifen modulate cellular plasticity cascades in animal model of mania. Journal of Psychopharmacology. 2012; 26(12): 1594-1604.

18. Armani F, Andersen ML, Andreatini R, Frussa-Filho R, Tufi k S, Fernandes GJ. Successful Combined Th erapy with Tamoxifen and Lithium in a Paradoxical Sleep Deprivation-Induced Mania Model. CNS Neuroscience & Th erapeutics 2012;18 (2) 119–125.

19. Abrial E, Lucas G, Scarna H, Haddjeri N, Lambás-Señas L. A Role for the PKC Signaling System in the Pathophysiology and Treatment of Mood Disorders: Involvement of a Functional Imbalance? Molecular Neurobiology. 2011 44(3):407–419.

20. Abrial E, Etievant A, Bétry C, Scarna H, Lucas G, Haddjeri N.et al. Protein kinase C regulates mood-related behaviors and adult hippocampal cell proliferation in rats. Progress in Neuro- Psychopharmacology & Biological Psychiatry 2013; 43 40–48.

21. Valvassori SS, Bavaresco DV, Budni J, Bobsin TS, Gonçalves CL, de Freitas. Et al KV. Eff ects of tamoxifen on tricarboxylic acid cycle enzymes in the brain of rats submitted to an animal model of mania induced by amphetamine. Psychiatry Research 2014; 215(2) 483–487.

22. Pereira M, Andreatini R, Schwarting RK, Brenes JC. Amphetamine-induced appetitive 50-kHz calls in rats: a marker of aff ect in mania? Psychopharmacology. 2014; 231(13):2567– 2577.

23. Manterola C, Daniela Z, Grupo MINCIR. Evidence-based clinical practice, levels of evidence. Rev. Chilena de Cirugía.2009; 61(6): 582-595.